Kindred Biosciences Announces Positive Opinion from CVMP in the European Union for Mirataz® (mirtazapine transdermal ointment) for Cats Experiencing Poor Appetite and Weight Loss

October 10, 2019

- Mirataz would be the first and only medication approved in the EU to treat cats...

Kindred Biosciences Secures $50 Million Debt Facility with Solar Capital Partners

October 2, 2019

  SAN FRANCISCO , Oct. 2, 2019 /PRNewswire/ --  Kindred Biosciences, Inc. (Nasdaq...

Kindred Biosciences Awarded a Contract by the National Cancer Institute in Support of the PREVENT Cancer Program

September 10, 2019

SAN FRANCISCO , Sept. 10, 2019 /PRNewswire/ --  Kindred Biosciences, Inc. (NASDAQ...

Kindred Biosciences to Participate in H.C. Wainwright Global Investment Conference, Lake Street Best Ideas Growth Conference, and Cantor Global Healthcare Conference

August 28, 2019

SAN FRANCISCO , Aug. 28, 2019 /PRNewswire/ --  Kindred Biosciences, Inc. (NASDAQ:...

Kindred Biosciences Announces Second Quarter 2019 Financial Results and Unveils Positive Results from Pilot Efficacy Study of Parvovirus Monoclonal Antibody

August 1, 2019

- Mortality benefit seen in both prophylaxis and treatment of parvovirus infectio...

Kindred Biosciences Announces Positive Results from Pilot Field Effectiveness Study of its Interleukin-31 Monoclonal Antibody for the Treatment of Atopic Dermatitis in Dogs

July 29, 2019

- Achieved rapid and dramatic reduction in pruritus (itch) and CADESI score versu...

Kindred Biosciences to Announce Second Quarter 2019 Financial Results

July 16, 2019

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time/1:30 p.m. P...

Kindred Biosciences to Participate in the B. Riley FBR Institutional Investor Conference, Stifel 2019 Dental & Veterinary Conference and 9th Annual LD Micro Invitational

May 13, 2019

SAN FRANCISCO , May 13, 2019 /PRNewswire/ --  Kindred Biosciences, Inc. (NASDAQ: ...

Kindred Biosciences Announces First Quarter 2019 Financial Results

May 9, 2019

SAN FRANCISCO , May 9, 2019 /PRNewswire/ --  Kindred Biosciences, Inc. (NASDAQ: K...

Kindred Biosciences to Announce First Quarter 2019 Financial Results

April 25, 2019

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time / 1:30 p.m....

Kindred Biosciences Announces Fourth Quarter and Full Year 2018 Financial Results

March 6, 2019

SAN FRANCISCO , March 6, 2019 /PRNewswire/ --  Kindred Biosciences, Inc. (NASDAQ:...

Kindred Biosciences to Announce Fourth Quarter and Year-End 2018 Financial Results

February 19, 2019

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time / 1:30 p.m....

Kindred Biosciences to Present at Bank of America Merrill Lynch Animal Health Summit and Barclays Global Healthcare Conference

February 13, 2019

SAN FRANCISCO , Feb. 13, 2019 /PRNewswire/ --  Kindred Biosciences, Inc.  (NASDAQ...

Kindred Biosciences Announces Closing of Public Offering of Common Stock and the Full Exercise of Underwriters' Option to Purchase Additional Shares

January 23, 2019

SAN FRANCISCO , Jan. 23, 2019 /PRNewswire/ --  Kindred Biosciences, Inc. (NASDAQ:...

Kindred Biosciences Named Best Company in North America by Leading Industry Publication

January 22, 2019

SAN FRANCISCO , Jan. 22, 2019 /PRNewswire/ --  Kindred Biosciences, Inc. (NASDAQ:...

Kindred Biosciences Announces Pricing of Public Offering

January 18, 2019

SAN FRANCISCO , Jan. 18, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: ...

Kindred Biosciences Announces Proposed Public Offering of Common Stock

January 17, 2019

SAN FRANCISCO , Jan. 17, 2019 /PRNewswire/ --  Kindred Biosciences, Inc. (NASDAQ:...

Kindred Biosciences Announces Positive Results from Pilot Field Effectiveness Study of epoCat™ for the Management of Non-Regenerative Anemia in Cats and Availability of Mirataz® at Banfield Pet Hospital

January 14, 2019

SAN FRANCISCO , Jan. 14, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: ...